IL-2 is named as an intervention in 22 current clinical trials in our China and USA registers. 15 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Essen Biotech (5). The most-studied condition is Breast Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2
NCT06920199 · ClinicalTrials.gov ↗ · cGVHD
|
Phase EARLY_PHASE1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | China |
|
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
NCT07646639 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiotherapy
|
Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | China |
|
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT05981014 · ClinicalTrials.gov ↗ · Breast Neoplasms
|
Phase 1/2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | China |
|
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685 · NHL, Multiple Myeloma, Blood Cancer
|
Phase 1/2 | Recruiting | Indapta Therapeutics, INC. | USA |
|
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
NCT06144671 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1/2 | Recruiting | Grit Biotechnology | China |
|
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
NCT06530303 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colon Cancer, Rectum Cancer
|
Phase 1/2 | Recruiting | Essen Biotech | China |
|
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
NCT06532799 · ClinicalTrials.gov ↗ · Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma
|
Phase 1/2 | Recruiting | Essen Biotech | China |
|
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
NCT06532812 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic
|
Phase 1/2 | Recruiting | Essen Biotech | China |
|
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT06538012 · ClinicalTrials.gov ↗ · Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell
|
Phase 1/2 | Recruiting | Essen Biotech | China |
|
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
NCT06640582 · ClinicalTrials.gov ↗ · Brain Tumor, Brain Metastases, Brain Cancer
|
Phase 1/2 | Recruiting | Essen Biotech | China |
|
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT03666000 · Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
|
Phase 1 | Recruiting | Imugene Limited | USA |
|
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
NCT03891706 · ClinicalTrials.gov ↗ · Solid Tumor
|
Phase 1 | Recruiting | Guangzhou FineImmune Biotechnology Co., LTD. | China |
|
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
NCT05881525 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1 | Recruiting | TCRCure Biopharma Ltd. | China |
|
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT06121570 · ClinicalTrials.gov ↗ · Breast Neoplasms
|
Phase 1 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | China |
|
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
NCT06302062 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
|
Phase 1 | Recruiting | Guangzhou FineImmune Biotechnology Co., LTD. | China |
|
Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
NCT06971913 · ClinicalTrials.gov ↗ · SLE (Systemic Lupus), CMV
|
Phase 2 | Not yet open | Peking University People's Hospital | China |
|
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
NCT07809724 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 2 | Not yet open | Peking University People's Hospital | China |
|
HS-IT101 Injection for Advanced NSCLC
NCT07105176 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer
|
Phase 1 | Not yet open | Qingdao Sino-Cell Biomedicine Co., Ltd. | China |
|
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)
NCT06577194 · ClinicalTrials.gov ↗ · Rectal Cancer, Advanced Solid Tumor
|
Phase 2 | Active, closed | The First Affiliated Hospital with Nanjing Medical University | China |
|
FT819 in Subjects With B-cell Malignancies
NCT04629729 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
|
Phase 1 | Active, closed | Fate Therapeutics | USA |
|
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
NCT05902520 · ClinicalTrials.gov ↗ · HNSCC, Melanoma, Gynecologic Cancer
|
Phase 1 | Active, closed | AgonOx, Inc. | USA |
|
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
NCT06255028 · Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies
|
Phase 1 | Active, closed | Century Therapeutics, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Neoplasms | 2 |
| Colorectal Cancer | 2 |
| Chronic Lymphocytic Leukemia | 2 |
| Advanced Solid Tumors | 2 |
| Rectal Cancer | 2 |
| Advanced Solid Tumor | 2 |
| NHL | 1 |
| Multiple Myeloma | 1 |
| Blood Cancer | 1 |
| Refractory Non-Hodgkin Lymphoma | 1 |
| Advanced Non-Small Cell Lung Cancer | 1 |
| cGVHD | 1 |
| Colon Cancer | 1 |
| Rectum Cancer | 1 |
| Stomach Cancer | 1 |
| Stomach Cancer Recurrent | 1 |
| Stomach Cancer, Adenocarcinoma | 1 |
| Esophageal Cancer | 1 |
| Brain Tumor | 1 |
| Brain Metastases | 1 |
| Brain Cancer | 1 |
| Glioma | 1 |
| SLE (Systemic Lupus) | 1 |
| CMV | 1 |
| Neuromyelitis Optica Spectrum Disorder (NMOSD) | 1 |
| Solid Tumor | 1 |
| Lung Cancer | 1 |
| Lung Cancer Metastatic | 1 |
| Lung Cancer, Non-small Cell | 1 |
| Lung Cancer Recurrent | 1 |
| Breast Cancer | 1 |
| Breast Carcinoma | 1 |
| Breast Cancer Metastatic | 1 |
| Breast Cancer Triple Negative | 1 |
| Non-Hodgkin Lymphoma | 1 |
| B-cell Acute Lymphoblastic Leukemia | 1 |
| Small Lymphocytic Lymphoma | 1 |
| Systemic Lupus Erythematosus | 1 |
| Lupus Nephritis | 1 |
| Idiopathic Inflammatory Myopathies | 1 |
| Diffuse Cutaneous Systemic Sclerosis | 1 |
| Lymphoma, B-Cell | 1 |
| Precursor B-Cell Acute Lymphoblastic Leukemia | 1 |
| HNSCC | 1 |
| Melanoma | 1 |
| Gynecologic Cancer | 1 |
| Radiotherapy | 1 |
| Tumor Associated Lymph Node T Cell | 1 |
| Immunotherapy | 1 |
| Lead sponsor | Trials |
|---|---|
| Essen Biotech | 5 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Peking University People's Hospital | 2 |
| Guangzhou FineImmune Biotechnology Co., LTD. | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Indapta Therapeutics, INC. | 1 |
| Qingdao Sino-Cell Biomedicine Co., Ltd. | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Imugene Limited | 1 |
| Century Therapeutics, Inc. | 1 |
| Fate Therapeutics | 1 |
| AgonOx, Inc. | 1 |
| TCRCure Biopharma Ltd. | 1 |
| Grit Biotechnology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 17 | 13 |
| Clinical trials in USA | 5 | 2 |
A trial with sites in more than one country appears in each of those registers.
22 current trials in our China and USA registers name IL-2 (also registered as Interleukin-2) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 15 of the 22 trials are recruiting: 13 with sites in China and 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Essen Biotech (5), Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2), Peking University People's Hospital (2) and Guangzhou FineImmune Biotechnology Co., LTD (2), among 14 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IL-2 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IL-2 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IL-2 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.